Kevin Lundquist has been appointed chief financial officer of Abzena Ltd, to be based in the US, where he will oversee the UK service company’s expansion. Mr Lundquist joins from Revance Therapeutics Inc where he was vice president of finance. Earlier in his career, he was chief financial officer at the Caterpillar Inc division in Japan. He later joined Oracle Corp and then Genentech, part of the Roche Group, where he was senior director of finance for the company’s global drug substance manufacturing operations.
Mr Lundquist earned a bachelor of science degree in accounting and finance from the University of Utah and a master’s degree in business administration from Utah State University, US.
Abzena announced the appointment on 1 February 2022.
Copyright 2022 Evernow Publishing Ltd